Accelerating RNA manufacturing with GMP-compliant
large-scale doggybone DNA (dbDNA™) technologies.
Authors
Tom Adie, Bhavana Kayyar, Michal Legiewicz, Jonathan Extance, Harvinder Pandha,
Sungwon Kim, Desislava Kuzeva and Benyamin Yazdan Panah
This poster was recently presented at the mRNA Process Development & Manufacturing Summit in Boston, MA.
Download a PDF version of the poster by completing the form below.
Download the poster here
What is doggybone DNA (dbDNA)?
dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences. It is approved in both Europe and the US as a starting material for the production of gene therapies in Phase I, and has several advantages over pDNA including:
- Optimal vector - Strong expression profile and eliminates bacterial sequences.
- Amplification of complex sequences - Long sequences, GC rich sequences and sequences with secondary structure (e.g., ITRs)
- Faster timeline to the clinic – GMP material available in a matter of weeks compared to months, removing DNA supply from your critical path.
How is dbDNA made?
With our proprietary enzymatic DNA production process, we can rapidly manufacture multiple grams of DNA using benchtop, disposable equipment.
Access dbDNA in different ways.
- Off-the-shelf catalogue products for initial evaluation
- Custom sequences from 5mg to 2.5g (non-GMP)
- cGMP material 100mg to 5g batches
- License and royalty free (when Touchlight manufacture)
Latest news
Touchlight completes expansion, creating one of the world’s largest DNA manufacturing facilities in London, UK. The facility capacity exceeds today’s global plasmid DNA demand and can enable commercialisation of genetic medicines.